¡Advertencia! El contenido en esta página está disponible solo en los siguientes idiomas: Inglés
COMECER (Castel Bolognese, RA, ITALY) together with its US subsidiary COMECER Inc. (Norristown, PA, USA) and Advaxis, Inc. (Princeton, NJ, USA), entered into an agreement for the production of an aseptic manufacturing system based on COMECER proprietary Isolation Technology, to be deployed for the development of Immunotherapies according to the Advaxis technology.
The system will be developed in the Italian COMECER facilities and will allow Advaxis to perform their unique Lm targeted Immunotherapy aimed at the production of a neoantigen immunotherapy, integrated within COMECER GMP grade isolation technology devices.
According to the process, the system will be used for processing and expanding attenuated strains of Lm, which will be then bioengineered to secrete an antigen-adjuvant fusion protein.
The preparation is then infused in the patient, creating potent innate immune stimulation. Due to the flexibility and adaptability of the platform and the manufacturing, the process can be adapted to target many different tumor types.
The system is being delivered as a combination of COMECER Isolators and the unique Flexycult mobile incubation
system, along with the integration of several other typical cell-processing laboratory devices. All the devices installed within the isolators respond to the highest standards for laboratory equipment and have been specially adapted for use in isolators.
Alessia Zanelli, CEO of Comecer Group: “When our equipment is used for such an important medical project, all of us at Comecer are proud. Being selected by Advaxis speaks to the quality of our solutions and confirms that our R&D investments are going in the right direction.”
Advaxis Inc. is a late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer.
Further information is available from www.advaxis.com
COMECER is a developer and manufacturer of high-tech systems in the field of Aseptic Processing and Containment for the Pharmaceutical and Nuclear Medicine Industries, specializing in isolation technology solutions for regenerative medicine and tissue engineering. COMECER’s products are used worldwide in hospitals, universities, research institutes, pharma companies and large industrial groups.
Further information is available from www.comecer.com